Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
2
Bullish
9
Bearish
35
Neutral
2
Bullish
9
Bearish
32
Neutral
0
Bullish
0
Bearish
3
Neutral
2
Bullish
9
Bearish
3
Neutral
2
Bullish
9
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Indo Amines Limited is a specialty chemicals manufacturer supplying aliphatic and aromatic amines and related intermediates across agrochemicals, pharmaceuticals, polymers, paints, pigments, inks and rubber chemicals, with five Indian manufacturing facilities and multiple international subsidiaries providing a global distribution and production footprint.
Financially, Indo Amines Limited reported consolidated H1 FY2026 revenue of Rs.58,505.72 lakh and consolidated profit after tax of Rs.4,695.18 lakh, reflecting mid-single-digit year‑on‑year margin expansion and operating margin around 14–15 percent, showing steady profitability despite elevated working capital and financing costs.
Working capital is a notable feature: consolidated trade receivables and inventories are large (trade receivables ~Rs.26,224.78 lakh consolidated), debtor turnover ratios imply extended collection cycles, while total borrowings are sizable (consolidated current borrowings ~Rs.22,526.80 lakh), producing a debt‑equity ratio near 0.85–0.89 and focused liquidity management needs.
Operationally Indo Amines Limited is investing in product expansion and capacity additions: a new Morpholine & derivatives product line was launched at the Dhule unit in FY2025 and the company recorded meaningful fixed asset additions and CWIP increases, signalling strategic focus on downstream aliphatic amines growth and incremental capex-led revenue potential.
Chemicals & Petrochemicals
Specialty Chemicals
887 Cr
High Risk
10.9
35.0
0.4
2.3
168.15
82.00
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY22
Indo Amines Ltd (INDOAMIN) is currently trading at 122.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Indo Amines Limited is a specialty chemicals manufacturer supplying aliphatic and aromatic amines and related intermediates across agrochemicals, pharmaceuticals, polymers, paints, pigments, inks and rubber chemicals, with five Indian manufacturing facilities and multiple international subsidiaries providing a global distribution and production footprint. Financially, Indo Amines Limited reported consolidated H1 FY2026 revenue of Rs.58,505.72 lakh and consolidated profit after tax of Rs.4,695.18 lakh, reflecting mid-single-digit year‑on‑year margin expansion and operating margin around 14–15 percent, showing steady profitability despite elevated working capital and financing costs. Working capital is a notable feature: consolidated trade receivables and inventories are large (trade receivables ~Rs.26,224.78 lakh consolidated), debtor turnover ratios imply extended collection cycles, while total borrowings are sizable (consolidated current borrowings ~Rs.22,526.80 lakh), producing a debt‑equity ratio near 0.85–0.89 and focused liquidity management needs. Operationally Indo Amines Limited is investing in product expansion and capacity additions: a new Morpholine & derivatives product line was launched at the Dhule unit in FY2025 and the company recorded meaningful fixed asset additions and CWIP increases, signalling strategic focus on downstream aliphatic amines growth and incremental capex-led revenue potential.
Over the past 52 weeks, Indo Amines Ltd has traded between a low of ₹82.00 and a high of ₹168.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Indo Amines Ltd has a market capitalization of approximately 887.38. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Indo Amines Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 10.92 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 887.38 Cr, Indo Amines Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Indo Amines Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Indo Amines Ltd is 10.92. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It occurred at Indo Amines’ manufacturing facility at Plot B-14, Mahad MIDC, District Raigad, Maharashtra.
Sales rose 30.27% year-on-year to ₹374.64 crore, and net profit increased 6.66% to ₹30.76 crore for the quarter ended June 30, 2026.
GPCB has issued a closure directive for Aarti Drugs’ Amines manufacturing operations at Saykha Industrial Estate for environmental non-compliance under the Water Act.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
804.05 | 965 Cr | 14.99 | 3.55 | 1.12 | 24.23 | 31.96 | 15.12 | ||
398.20 | 948 Cr | 32.57 | 4.88 | 0.00 | 15.06 | 18.76 | 13.33 | ||
744.10 | 937 Cr | 39.43 | 3.33 | 0.00 | 8.44 | 10.48 | 5.97 | ||
122.25 | 887 Cr | 10.92 | 2.26 | 0.41 | 20.22 | 18.45 | 9.05 | ||
941.70 | 828 Cr | 22.83 | 3.28 | 0.32 | 11.74 | 17.68 | 11.89 | ||
31.25 | 780 Cr | 31.18 | 4.68 | 0.00 | 15.03 | 12.76 | 4.61 | ||
586.75 | 725 Cr | 24.33 | 5.13 | 0.26 | 21.08 | 29.09 | 15.32 | ||
| Median: 7 Co. | — | 586.75 | 887 Cr | 24.33 | 3.55 | 0.26 | 15.06 | 18.45 | 11.89 |
